CD44 and neoplasm: Clinical analyses from 2023 and 2024 also connect CD44 expression with increased tumour grade, triple-negative or ER-negative, lymph node involvement and worse outcomes, suggesting that CD44 can be considered a prognostic marker and clinical indicator for cancer stem-based interventions in the breast TME [268,269].